Timing of REGEN-COV administration and progression to severe COVID-19

INTRODUCTION: Several clinical trials have demonstrated that REGEN-COV (casirivimab and imdevimab) decreases the risk of hospitalization and death among COVID-19 patients. However, these trials did not evaluate the optimal timing of its administration, and evidence is limited regarding the relations...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Tomoka, Imajou, Sato, Matsumoto, Naomi, Takao, Soshi, Yorifuji, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265142/
https://www.ncbi.nlm.nih.gov/pubmed/35817250
http://dx.doi.org/10.1016/j.jiac.2022.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265142/
https://www.ncbi.nlm.nih.gov/pubmed/35817250
http://dx.doi.org/10.1016/j.jiac.2022.07.002

Ejemplares similares